Heather Wakelee is a thoracic medical oncologist with a passion for research into pleural region cancers, including mesothelioma.
- Participating in ongoing clinical trials involving agents specifically targeted to known mutations in lung cancer (epidermal growth factor receptor (EGFR)-targeted agents, anti-angiogenesis agents, and Met-targeted drugs such as onartuzumab, tivantinib and cabozantinib).
- Principal investigator of a large adjuvant trial for patients with completely resected lung cancer who are randomized to chemotherapy or chemotherapy plus bevacizumab.
- Collaborating with thoracic surgery and radiation oncology specialists in a multidisciplinary trial for Stage III, non-small cell lung cancer patients and in another trial for establishing CyberKnife protocols in early stage cases where the patient is ineligible for surgery.
- Chairs a research working group looking into understudied rare malignant diseases.
- Teaches at Stanford University Medical Center.
- Won teaching awards from Stanford University Division of Oncology (2007, 2008, 2009, 2011), medical honor-society recognition from Alpha Omega Alpha (Johns Hopkins University 1996), and an award of merit from American Society of Clinical Oncology (2003).
- Member of the Eastern Cooperative Oncology Group.
- M.D. degree from Johns Hopkins University School of Medicine.